NTII Neurobiological Technologies (MM)

BOCA RATON, Fla., Jan. 30 /PRNewswire-FirstCall/ -- Dawson James Securities, a full-service investment firm serving the healthcare and biotechnology industry, initiated research coverage on Neurobiological Technologies, Inc. (NASDAQ:NTII) with a Speculative Buy rating and a 12-18 month price target of $7.00. Stephen M. Dunn, Director of Research, issued the report. The report describes Neurobiological Technologies business and drug pipeline. Mr. Dunn states "With Viprinex(R) for acute ischemic stroke representing the higher risk/higher reward drug and XERECEPT(R) representing the lower risk/lower reward drug with Neurobiological Technologies Memantine royalty stream providing some downside protection, we feel Neurobiological Technologies overall risk reward profile is favorable for investors." A copy of the report may be obtained by contacting Dawson James Securities at 561-391-5555. About Dawson James Securities: Dawson James Securities is a full service investment firm with deep expertise in healthcare and biotechnology and having a staff of over 50 investment professionals providing institutional research, investment banking and high net worth services to our clients. More information is available at http://www.dawsonjames.com/ Disclosures: Dawson James has not acted as an investment banker for the company mentioned in this report in the past, although Dawson James may have sought in the past, or may actively seek in the future, compensation for investment banking services. The analyst certifies that 1) all of the views expressed accurately reflect his personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst; 3) the analyst responsible for preparing this research report receives compensation based upon various factors, including total revenues of Dawson James and its affiliates, a portion of which is generated by investment banking activities and 4) the analyst and/or members of their immediate family do not own stock in the companies mentioned. Contact: Dawson James Securities Stephen M. Dunn, 561-208-2905 Fax: 561-391-5757 Dawson James Securities is a member of the National Association of Securities Dealers, CRD number 130645. DATASOURCE: Dawson James Securities CONTACT: Stephen M. Dunn of Dawson James Securities, +1-561-208-2905, or fax, +1-561-391-5757 Web site: http://www.dawsonjames.com/

Copyright